Research Analysts Set Expectations for ACAD FY2026 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for ACADIA Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Kim anticipates that the biopharmaceutical company will post earnings of $0.85 per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

A number of other research analysts have also recently issued reports on ACAD. Mizuho lifted their target price on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the company a “neutral” rating in a research note on Monday, May 19th. JPMorgan Chase & Co. increased their price objective on shares of ACADIA Pharmaceuticals from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, June 6th. Oppenheimer reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, May 16th. Deutsche Bank Aktiengesellschaft raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the stock from $20.00 to $35.00 in a report on Wednesday, May 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $26.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 19th. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.79.

ACADIA Pharmaceuticals Trading Down 0.4%

NASDAQ:ACAD opened at $22.20 on Tuesday. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $25.23. The firm has a 50 day moving average of $17.59 and a 200-day moving average of $17.73. The stock has a market capitalization of $3.72 billion, a P/E ratio of 28.46 and a beta of 0.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company had revenue of $244.32 million during the quarter, compared to analysts’ expectations of $239.32 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 18.7% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in ACADIA Pharmaceuticals by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock worth $252,526,000 after acquiring an additional 1,255,594 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in ACADIA Pharmaceuticals during the 1st quarter worth approximately $60,845,000. Fred Alger Management LLC boosted its stake in ACADIA Pharmaceuticals by 2.0% during the 1st quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company’s stock worth $46,007,000 after acquiring an additional 54,899 shares during the last quarter. First Trust Advisors LP boosted its stake in ACADIA Pharmaceuticals by 27.0% during the 4th quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company’s stock worth $49,547,000 after acquiring an additional 574,251 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in ACADIA Pharmaceuticals during the 4th quarter worth approximately $40,935,000. Institutional investors own 96.71% of the company’s stock.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the company’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $14.60, for a total transaction of $51,070.80. Following the completion of the sale, the executive vice president now owns 62,773 shares in the company, valued at approximately $916,485.80. The trade was a 5.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James Kihara sold 4,000 shares of the company’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $22.50, for a total transaction of $90,000.00. Following the sale, the insider now owns 20,395 shares of the company’s stock, valued at $458,887.50. The trade was a 16.40% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,273 shares of company stock valued at $653,182. 26.50% of the stock is currently owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.